Dr Reddy’s Labs Share Value Goal: Dr Reddy’s Laboratories, a multinational pharmaceutical firm, on Wednesday, July 23, introduced its monetary efficiency for the primary quarter of FY26.
The has posted a web revenue at Rs 1,410, a one per cent improve within the June quarter.
The Hyderabad-based drug maker’s income elevated to Rs 8,545 crore in the course of the interval towards Rs 7,673 crore YoY. After this growth, what ought to traders do with the agency’s inventory? Analysts at world brokerages—Goldman Sachs, JPMorgan, Jefferies, CLSA, Morgan Stanley, Citi, and HSBC—have combined stances after the pharma agency’s earnings. Here’s what they advocate:
Goldman Sachs has maintained a ‘impartial’ ranking on Dr Reddy’s Labs shares, elevating share value goal to Rs 1,200 from Rs 1,175.
JPMorgan has maintained an ‘underweight’ ranking on the foremost pharma inventory with a goal of Rs 1,090, which raised from Rs 1,060. Whereas Jefferies has maintained an ‘underperform’ stance on the inventory, rising the goal value to Rs 1,100 from Rs 1,010.
(This story will likely be updates shortly.)
